| Статус: | Unknown status |
| Фаза: | не указано |
| Начало: | 1 июня 2020 г. |
| Окончание: | 1 декабря 2022 г. |
| Описание: | The purpose of this study is to assess safety of Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression during or after therapy with a prior EGFR tyrosine kinase inhibitor (TKI), with confirmed Т790М positive mutation in EGFR gene. |
| смотреть на ClinicalTrials.gov |